atorvastatin has been researched along with Essential Hypertension in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, H; Liu, Z; Luo, W; Ouyang, F; Tang, L; Yan, Y; Yang, H; Yuan, W | 1 |
| Bespalova, ID; Kaliuzhin, VV; Mediantsev, IuA; Murashev, BIu; Osikhov, IA; Riazantseva, NV | 1 |
1 trial(s) available for atorvastatin and Essential Hypertension
| Article | Year |
|---|---|
Effect and mechanism of HMG-CoA reductase inhibitor on the improvement of elderly essential hypertension-induced vascular endothelial function impairment based on the JAK/STAT pathway.
Topics: Aged; Amlodipine; Animals; Atorvastatin; Essential Hypertension; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Janus Kinases; Rats; Rats, Inbred SHR; Signal Transduction; STAT Transcription Factors | 2023 |
1 other study(ies) available for atorvastatin and Essential Hypertension
| Article | Year |
|---|---|
[Effect of atorvastatin on pro-inflammatory status (in vivo and in vitro) in patients with essential hypertension and metabolic syndrome].
Topics: Anticholesteremic Agents; Atorvastatin; Cytokines; Dose-Response Relationship, Drug; Drug Monitoring; Essential Hypertension; Female; Heptanoic Acids; Humans; Hypertension; Inflammation; Leukocytes, Mononuclear; Male; Metabolic Syndrome; Middle Aged; Patient Acuity; Prospective Studies; Pyrroles; Reactive Oxygen Species; Severity of Illness Index; Treatment Outcome | 2014 |